By Gina Shaw
Biosimilar infliximab (CT-P13/Inflectra, Celltrion) is not inferior to the originator product, Remicade (Janssen), in treating rheumatoid arthritis and five other chronic inflammatory diseases, according to findings from the NOR-SWITCH trial presented at the 2016 United European Gastroenterology meeting.